Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9264624 | 1.00 | SLC1A3 (0.34) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL6216660 | 0.96 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL16059792 | 0.85 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL27671067 | 0.85 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL10351575 | 0.85 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL3007008 | 0.85 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL9095023 | 0.85 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL4601140 | 0.81 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL5271501 | 0.81 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL1560449 | 0.81 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908989-B2 | Process for the production of perbenzylated 1-O-glycosides | SCHERING AG (DE) | 2005-06-21 | — | — | US | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6831164-B2 | Generation of peracylated 1-O-glycosides; obtain chemical intermediate, react with alkylating agent, heat and recover product | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-14 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-6641797-B2 | As contrast media for the visualization of malignant tumors, lymph nodes and necrotic tissue | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-04 | — | — | US | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20030069402-A1 | Process for the production of peracylated 1-0-glycosides | SCHERING AG (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6545135-B2 | Alkylation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| US-20020076379-A1 | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | SCHERING AKTIENGESELLSCHAFT | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020076379-A1 | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use | FGB, MSR1, FFAR1 | SLC1A3 2673/4885SLC1A2 3357/4885SLC1A1 2364/4885 |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | SLC1A3 2512/4885SLC1A2 3422/4885SLC1A1 2529/4885 |
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | MAN1B1, STT3B, OSTC | SLC1A3 3529/4885SLC1A2 4064/4885SLC1A1 3391/4885 |
| US-20030069402-A1 | Process for the production of peracylated 1-0-glycosides | B3GNT2, UGT8, UGGT1 | SLC1A3 2573/4885SLC1A2 2688/4885SLC1A1 2279/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | SLC1A3 2410/4885SLC1A2 3659/4885SLC1A1 2611/4885 |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | STT3B, MAN1B1, OSTC | SLC1A3 3431/4885SLC1A2 3834/4885SLC1A1 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.